Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have discovered a genetic mutation in the DKC1 gene that causes a rare, fatal X-linked recessive disease characterized by premature aging, bone marrow failure, and increased cancer risk. The study suggests that ribosome dysfunction, rather than telomerase impairment, is the primary cause of this syndrome.
Researchers have identified a mutated form of the enzyme PDGFRA, which is found in many body tissues and may trigger gastrointestinal stromal tumors. The study validates a novel molecular technology that can be used to find additional targets for cancer treatments.
Researchers found that tamoxifen stimulation increased mature eggs and embryos compared to natural cycle IVF, with one patient already giving birth to twins. A larger study is planned to include low amounts of FSH for additional benefits.
Researchers have discovered that combining Avastin with chemotherapy provides superior treatment for advanced colorectal cancer, increasing median survival by 8.3 months and response rates. The study's findings suggest a more effective and less toxic option for patients with this devastating form of cancer.
Researchers at Brigham Young University have successfully tested a new method to concentrate the impact of cancer drugs on specific tissues, sparing healthy areas. The method uses tiny water-soluble plastic particles and ultrasound to release the drug at the tumor site, significantly reducing tumor size in laboratory animals.
Researchers inserted a firefly gene into mice with cancer, allowing them to detect cell death in real-time. The technology uses luciferase to emit light only when cells start dying, enabling rapid testing of new drugs for cancer and other diseases.
Researchers investigated the association between alcohol consumption and lung cancer risk, finding no statistically significant link. The Journal of National Cancer Institute also published studies on body surface area-based dosing for anticancer drugs and carbohydrate binding protein's potential to inhibit tumor growth.
The Wistar Institute's MAb425 antibody has shown promising results in a Drexel University trial, with three high-grade tumor patients alive after five years and eight lower-grade tumor patients surviving for 56 months or longer.
Researchers discovered that tamoxifen-resistant breast cancer cells alter their traits and become responsive to Herceptin and other HER-2 targeted drugs. A new GlaxoSmithKline drug, GSK572016, shows promise in shrinking tumors resistant to both tamoxifen and Herceptin.
A new gene profiling technique could help predict which breast cancer patients will respond to hormonal therapies and which will require additional chemotherapy. The study aims to identify the cellular programs that must be engaged or shut off for aromatase inhibitors to be successful.
Researchers at Dana-Farber Cancer Institute found that combination therapy of cytarabine, daunorubicin, and Mylotarg achieved complete remission in 83% of evaluable participants. The treatment was well-tolerated, with no significant increase in side effects.
A Phase II study of CC-5013, a thalidomide-like compound, has shown significant anti-myeloma activity with measurable responses in about 50 percent of evaluable patients. The drug has been well tolerated, with evidence that the daily dosing regimen has fewer side effects than the twice daily schedule.
In a Phase II clinical trial, VELCADE (bortezomib) produced partial responses in 32% of patients with relapsed or refractory myeloma. The overall response rate was 35%, with some patients continuing to show positive responses nearly a year after treatment.
A new 'designer' drug has shown activity in treating acute myeloid leukemia (AML), with 13 of 15 patients experiencing reductions in abnormal white blood cell counts. The experimental compound targets a specific genetic flaw, offering a more targeted approach to conventional chemotherapy drugs.
The Salk Institute and SUGEN scientists have created a detailed catalog of the 518 protein kinase genes encoded by the human genome. This comprehensive mapping will enable the development of new drugs targeting kinases, offering an alternative to standard chemotherapy for specific types of cancer.
A phase I trial using rViscumin administered intravenously has begun in Hanover and Nantes, France, with preliminary results showing immune system responses to the drug. The trials are part of further Phase I studies being considered, which will determine the clinical significance of rViscumin.
Research in mice found that rapamycin combined with radiation treatment delayed the regrowth of glioblastoma multiforme (GBM) human tumors by an average of 19 days. Rapamycin inhibits the activity of mTOR, a protein promoting tumor growth, and its combination with radiation may enhance chemotherapy efficacy.
A Phase I study of the novel anti-angiogenic drug SU011248 showed promising results in patients with advanced cancers that had failed to respond to other therapies. The drug demonstrated activity in a range of tumour types, including renal and gastrointestinal cancers, but did not show efficacy against brain metastases.
Researchers found that inhibiting PDGF signalling increases tumour uptake of cytotoxic drugs without increasing toxicity. Combination therapies with Glivec and other drugs induced better anti-tumour effects in animal models, suggesting a new strategy for improving drug treatment for cancer patients.
Researchers use firefly protein to visualize cellular communication pathways in mice, revealing potential for non-invasive cancer treatment and disease research. This breakthrough enables scientists to watch proteins in their natural setting, improving understanding of human diseases.
A phase II clinical trial shows the oral combination of thalidomide and dexamethasone reduces tumor size by 50% or more in 64% of newly diagnosed multiple myeloma patients. This treatment alternative offers a promising solution to chemotherapy's side effects, including nausea, vomiting, and hair loss.
A new strategy in cancer treatment involves using genetic information to guide drug delivery, allowing for more targeted and efficient treatments. The approach uses nucleic acid-triggered catalytic drug release, recognizing and responding to unique cancerous sequences to deliver potent anticancer drugs.
A new trial shows that high-dose chemotherapy has no significant benefits for women with severe breast cancer. However, molecularly targeted drugs in combination with chemotherapy show promising results.
Early results of North American trials of oxaliplatin show a 70% delay in tumour progression and significant improvement in symptoms for patients with advanced bowel cancer. The US FDA has approved the drug for use in these patients.
Professor Edzard Ernst urges oncologists to be open to alternative medicines, as desperation drives patients to try anything. He warns that some therapies can be dangerous and advises patients to consult with healthcare professionals before trying new treatments.
Researchers have discovered a novel compound that kills bad immune cells while leaving healthy ones intact, offering hope for safer and more effective treatments for lupus. The compound, Bz-423, targets a protein in immune cells' mitochondria, showing promise in treating autoimmune diseases and potentially some types of cancer.
The American Association for Cancer Research (AACR) is calling on the FDA to accelerate the development and approval of chemopreventive agents for precancerous cells. Emerging technologies have improved detection capabilities, but drug approvals remain limited due to concerns about treatment efficacy in high-risk populations.
A study in the Journal of the National Cancer Institute found that women undergoing prophylactic bilateral mastectomy often overestimate their breast cancer risk. Meanwhile, a separate study uncovered no association between antiperspirant use and increased breast cancer risk. Furthermore, researchers identified a serum protein expressi...
Researchers found that hormones bind to specific receptors in cells, recruiting co-activators to regulate gene expression and alter protein production. This process enables a vast range of protein diversity from relatively few genetic sources.
A team of researchers from Duke University has made significant breakthroughs in understanding the mechanism of FTase, a key player in cancer development. The study revealed that FTase doesn't release its product until another substrate molecule arrives, suggesting a new role for the enzyme beyond molecular seamstressing.
Healthy, nondividing cells have a biochemical switch that triggers apoptosis when inactivated by deamidation of Bcl-xL protein. This discovery suggests that tumor cells with the same switch may be resistant to chemotherapy drugs.
Sporn's groundbreaking research on chemoprevention has revolutionized the field of cancer prevention, exploring novel approaches to prevent or treat cancer. His work has led to strategies with vast potential for reducing cancer incidence and death, and continues to inspire new directions in cancer prevention research.
Researchers have identified three new genes in a rhesus monkey rhadinovirus with high structural similarity to those in human herpesvirus-8, paving the way for future studies using recombinant viruses. The goal is to develop targeted drug therapies against specific KSHV genes to prevent virus spread and cancer induction.
Dr. Michael Sporn, a renowned cancer researcher, has made significant contributions to cancer prevention through his work on chemoprevention and the development of new strategies to reduce cancer incidence and death. He is recognized for his pioneering studies on the role of Vitamin A and retinoids in cancer prevention.
The study tracked the movement of individual cancer cells in real-time using computer automation. The research revealed similarities between breast and skin cancer strains, including oscillation and burrowing into tissue.
Researchers conducted a Phase I clinical trial of endostatin, showing that it decreases blood flow to tumors and promotes the death of cancer cells. The study also found minor anti-tumor activity in two patients, but no long-term responses were seen.
The National Functional Genomics Project aims to track genetic changes in cancer to design more effective therapeutic agents and understand hereditary and environmental influences. Moffitt's expertise in translational research will accelerate the translation of molecular medicine into early detection and clinical treatment.
Researchers discovered tetrathiomolybdate (TM) inhibits tumor angiogenesis by reducing copper levels and blocking NFkB signaling pathway. TM suppressed tumor growth in mice with aggressive breast cancer, prevented blood vessel formation, and induced disease-free survival.
A study of 270 patients found that bladder cancer recurrence rates increased with each episode, with the average time to second and third recurrences decreasing by 15 and 13 months respectively. Patients whose original tumors tested positive for the Ki-67 marker were at higher risk for first recurrence.
Researchers at Penn State have identified a protein, km23, that is defective in nearly half of human cancer tissues. Alterations in this protein disrupt cell signaling, leading to tumor growth and spreading. The team hopes to develop drugs targeting km23 to prevent tumor progression and diagnose specific cancers.
A recent analysis of eight PC-SPES lots revealed widespread contamination with indomethacin and diethylstilbestrol, two potent synthetic compounds that undermine the supplement's anticancer potency. The study suggests that the contaminated batches had significantly reduced anticancer activity.
Researchers at Cedars-Sinai Medical Center found that a cancer drug caused a virus to mutate so much it could no longer reproduce, becoming extinct. The treatment increases mutations in viral genomes, making it a promising approach to combat viruses.
A study has characterized a significant family of signaling proteins in the human genome, identifying 60 previously unknown protein kinases. The comprehensive analysis provides valuable insights into understanding the relationships between protein kinase structures and functions.
Researchers at University College London have discovered a potential new cancer treatment using compounds found in cola beverages, coffee, tea, and chocolate. The compounds block the operation of a key enzyme linked to cell growth and blood clotting.
A study found that St. John's wort significantly lowers blood levels of irinotecan's active metabolite SN-38 by 42%, decreasing detoxification and reducing overall antitumor activity. Patients receiving chemotherapeutic treatments with St. John's wort may need to increase drug dosage.
A synthetic compound called oxomate has been developed to target breast cancer, with promising results in animal tests and potential for a once-a-day pill or vitamin component. If confirmed, oxomate could offer an alternative to current treatments and provide benefits to those at high risk of cancer
Researchers at UW-Madison have identified genetic elements in soil-dwelling bacteria that produce potent anticancer agents. The discovery enables mass production and manipulation of these chemicals, offering a promising alternative to existing treatments.
A new study from the International Collaborative Ovarian Neoplasm (ICON) Collaborators found that paclitaxel plus carboplatin produces similar effectiveness to other treatments for women with ovarian cancer, but with more serious side effects. Carboplatin may be considered a preferred treatment option due to its better toxicity profile.
A Cornell University biochemist has developed a strategy to make tumor cells more sensitive to retinoic acid, reducing required doses and enhancing its anticancer activity. By introducing CRABP-II, a naturally occurring protein, researchers can boost RA's ability to inhibit breast cancer cell proliferation.
Cornell researchers have found that a longer infusion time of boronophenylalanine is needed to effectively target cancer cells in brain tumors. The new finding has the potential to improve the success of boron neutron capture therapy, which has shown moderate success in treating tumors but struggles with aggressive cell clusters.
A study by University of Minnesota researchers found that morphine activates the MAPK signaling pathway in human endothelial cells, promoting angiogenesis and tumor growth. The findings could lead to new treatments for managing cancer pain while minimizing tumor growth.
Researchers found that neighborhoods with older homes in urban areas have sidewalks, denser street networks, and mix of business and residential uses, which encourages walking. Men and non-Hispanic whites were more likely than women and other racial groups to walk at least a mile 20 times a month.
The World Health Organization predicts 15 million new cancer cases annually by 2039, with 70% occurring in developing countries. Anti-cancer factions are pooling knowledge and resources to establish a system to better equip healthcare organizations for the growing challenge.
A new study suggests that medications like tamoxifen and raloxifene could potentially lower the risk of breast cancer in women at high risk. These drugs have shown to decrease the likelihood of breast cancer by up to 50% in some cases, but they also carry side effects such as blood clots and hot flashes.
A new study found that anastrozole improved disease-free survival and was better tolerated than tamoxifen. Anastrozole may be a viable alternative to tamoxifen for adjuvant treatment of early breast cancer in postmenopausal women.
A new study found that anastrozole improved disease-free survival and was better tolerated than tamoxifen, a current standard treatment. The ATAC trial also showed no additional benefit from combining both drugs.
The Society of Nuclear Medicine announced its Image of the Year, showcasing an innovative PET scan for detecting lung cancer in a patient with dermatomyositis. The image also highlights a groundbreaking study on dopamine transporters in mouse brains using ultra-high resolution SPECT.
A study by Dartmouth/VA researchers found that major US news media favored routine use of screening mammography and urged caution about tamoxifen, with greater emphasis on the negative aspects of the latter. The coverage of these issues highlights the need for balanced media reporting to focus on science rather than emotions or politics.
A study of female radiologic technologists found that prolonged exposure to low dose radiation is associated with a higher risk of breast cancer mortality. Women who started working as radiologic technologists before 1940 were nearly three times more likely to die from breast cancer than those who began working in 1960 or later.
A study using PET/CT scans found that 58.8% of patients had at least one positive focus of FDG uptake in the thoracic aortic wall, which may indicate 'vulnerable' plaque. This could lead to future cardiovascular events if left untreated.